Volu-Sol Reagents Corp company manufactures diagnostic products for use by clinical laboratories; it also plans to provide personal emergency response products and services for consumers. The company's diagnostic business develops and manufactures chemical reagents, stains, and related equipment used by laboratories to detect certain properties in biological samples in fields such as hematology and microbiology. Volu-Sol's yet to be launched Insight Care services employ biosensors, cell phone, and GPS technology to remotely monitor a client's vital signs and provide assistance. Parent RemoteMDx is spinning off Volu-Sol to shareholders. Founded in 1991, ActiveCare (formerly Volu-Sol) has been aided by some of the world’s largest companies, including Matsushita Electric Works (Panasonic), which was not only an investor in the company, but has helped to shape its technologies.

Chesapeake Biological Laboratories (CBL) provides product development and commercial drug production services for pharmaceutical and biotechnology companies. It also manufactures experimental drugs for use in clinical trials. The company specializes in biopharmaceuticals, materials derived from naturally occurring biological substances. CBL's primary operations are sterilizing and filling liquid drugs and production lyophilization, the process of filling drug containers while limiting the product's exposure to room temperature. CBL is a wholly-owned subsidiary of Canadian biopharma firm Cangene.

Premier Research Group, Ltd. was founded in 2002 and is based in Wokingham, United Kingdom. Premier Research Group, Ltd., a contract research organization, provides clinical trial management and information services to the pharmaceutical and biotechnology industries in Europe, Asia, Africa, Australia, Latin America, and North America. The company focuses its research and development program on enhancing software systems used to support its clinical trials management and information services. Its services include dedicated clinical sites, medical and safety management, medical writing, data management, biostatistics, interactive voice response systems, regulatory affairs, and quality assurance. The company conducts its clinical research in the areas of infectious diseases, oncology, pediatrics, analgesia, and CNS. The company was formerly known as CRC Development Limited and changed its name to Premier Research Group, Ltd. in November, 2004.

SurModics, Inc. Company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates through four business units: Cardiovascular, Ophthalmology, SurModics Pharmaceuticals, and In Vitro Technologies. The Cardiovascular business unit supports the drug delivery and surface modification needs of cardiovascular customers by providing drug delivery polymers and coating technologies, including advanced lubricity (slippery) coatings that ease placement and maneuverability of medical devices in the body. The Ophthalmology business unit develops drug delivery systems for various drugs and other bioactive agents developed by pharmaceutical and ophthalmology companies for the treatment of serious eye diseases.The SurModics Pharmaceuticals business unit specializes in proprietary injectable microparticles and implants based on biodegradable polymers to provide sustained delivery of drugs, as well as supplies biodegradable polymers to corporate and academic customers. The In Vitro Technologies business unit specializes in in vitro diagnostic products and technologies for the biomedical research and medical diagnostic markets. Its products and technologies include protein stabilization reagents, substrates, recombinant autoimmune antigens, surface chemistry technologies for nucleic acid and protein immobilization, and diagnostic format intellectual property. The company markets its technologies and products through sales professionals, as well as sales and marketing relationships with third-parties worldwide. It has collaboration agreements with Genzyme Corporation to develop novel drug delivery solutions with an initial focus on peptide delivery.

StemCells, Inc. company was founded in 1988 and is based in Palo Alto, California. StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

Forest Laboratories, Inc. was founded in 1956 and is based in New York, New York. Forest Laboratories, Inc. develops, manufactures, and sells branded and generic forms of ethical drug products. Its principal products include Lexapro to treat depression; Namenda to treat Alzheimer's disease; Bystolic, beta-blocker to treat hypertension; and Savella for the treatment of fibromyalgia. The company also provides Sudocrem, a topical preparation to treat diaper rash; Colomycin, an antibiotic to treat cystic fibrosis; Infacol, which is used to treat infant colic; and Exorex, which is to treat eczema and psoriasis. In addition, its products include Dutogliptin, a small molecule dipeptidyl-peptidase-4 inhibitor, which is in Phase III studies to treat Type II diabetes mellitus; F2695 that completed Phase II study and is a selective norepinephrine and serotonin reuptake inhibitor for the treatment of depression and other central nervous system disorders; and ceftaroline acetate, a injectable cephalosporin antibiotic that exhibits bactericidal activity against the strains of gram-positive bacteria.Forest Laboratories'sproducts comprise NXL104, an intravenous beta-lactamase inhibitor; Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation; Aclidinium, an inhaling therapy, which is in Phase III studies for chronic obstructive pulmonary disease; and Cariprazine, an atypical antipsychotic in Phase II(b) studies for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions. Additionally, its products include Oglemilast, a phosphodiesterase-IV inhibitor in Phase II study to treat COPD and asthma; and Benicar, an angiotensin receptor blocker to treat hypertension. The company has collaboration and license agreements Phenomix Corporation, Pierre Fabre Medicament, Novexel, S.A., Laboratorios Almirall, S.A., Gedeon Richter Ltd., Glenmark Pharmaceuticals Ltd., and AstraZeneca plc.

Cedarburg Hauser, formerly Cedarburg Pharmaceuticals, makes drugs, components of drugs, and ingredients for drugs. The contract manufacturer does everything from project management to manufacturing to validating study results. It produces custom chemicals, natural and synthetic active pharmaceutical ingredients, dietary supplements, and cosmetics. And, because Cedarburg Hauser also holds Drug Enforcement Agency permits, it makes controlled substances including pain killers and other narcotics. Other services include process development and a whole host of analytical services including quality control and stability studies.

Promega helps researchers plumb the depths of the life sciences. The company sells more than 2,000 products that allow scientists to conduct various experiments in gene, protein, and cellular research. Its reagents and other goods fall into more than two dozen categories, including DNA and RNA purification, genotype analysis, protein expression and analysis, and DNA sequencing. Promega has branches in about a dozen countries around the world. The firm sells its products directly and through more than 50 distributors. Customers include academic, pharmaceutical, and clinical labs, as well as government agencies and energy and chemical companies.

IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE Biotechnology, Inc. engages in the development, production, and marketing of specialty biochemical products in the United States and internationally. It focuses on research and development in the areas of fermentation technology, nutrition and health, and marketing of products and applications. The company offers AstaXin, a natural source of astaxanthin, a pigment that imparts the characteristic red color to the flesh of salmon, trout, prawns, and other types of fish and shellfish. It is also venturing to supply astaxanthin as a nutraceutical ingredient. The company sells AstaXin primarily to fish producers in the aquaculture industry principally in the European Union, Japan, Chile, and Canada. IGENE Biotechnology, Inc. has a joint venture agreement with Archer-Daniels-Midland Company to manufacture and sell astaxanthin and derivative products worldwide.

Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of various disease states, including hematologic and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. The company primarily markets Soliris (eculizumab) in the United States and Europe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It is also evaluating other indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, the company is developing Anti-CD200 antibody for the treatment of B-Cell Chronic Lymphocytic Leukemia, a cancer that results from expansion of B-lymphocytes and other cancers.Alexion Pharmaceuticals drug programs include Eculizumab (intravenous), a phase II product candidate for atypical HUS, presensitized renal transplant, myasthenia gravis, multifocal motor neuropathy, dense deposit disease, catastrophic antiphospholipid syndrome, and cold agglutinin disease; CD200 Mab, which is in phase I/II clinical trial for the treatment of chronic lymphocytic leukemia and in preclinical stage for the treatment of multiple myeloma; and Eculizumab (new formulation) that is under phase I/II clinical trial for the treatment of asthma. Its customers include specialty distributors and specialty pharmacies who supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, and other health care providers and distributors.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.